← Back to IPO List

Braveheart Bio

Last updated: August 2, 2026
Ticker
BRVE
Exchange
NYSE
IPO Date
Pending
Price Range
$15.00 - $17.00
Deal Size
$300 million

Company Snapshot

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor designed to improve treatment options for obstructive and non-obstructive HCM. Braveheart Bio aims to enhance the speed of onset, depth of gradient response, and reduce prescribing complexity for patients.

Founded
2024

Key Financials

Metric202520242023
RevenueNot providedNot providedNot provided
Adjusted Net Loss-$66.1MNot providedNot provided

Balance Sheet

Cash & Equivalents
$89.2M

Implied Valuation at Midpoint

Market Cap
$1.1B

Based on price range midpoint and most recent fiscal year data.

S-1 Highlights

Market & Competition

The company operates in the cardiovascular disease market, specifically targeting hypertrophic cardiomyopathy. Braveheart Bio competes with established companies such as MyoKardia, which markets mavacamten (Camzyos), and Bristol Myers Squibb, which markets aficamten (Myqorzo).

Use of Proceeds

The proceeds from the IPO are expected to be used to fund clinical trials for BHB-1893 and for general corporate purposes.

Key Risk Factors

  • ●The company faces significant competition from larger firms with established market share and resources, which may hinder its ability to compete effectively.
  • ●There is no prior public market for Braveheart Bio's common stock, which may result in volatility and uncertainty regarding the trading price.

Deal Structure

Primary Shares
18,750,000 shares
Shares Outstanding
70,652,838 shares
Post-IPO Float
26.6%
Lock-up
No Lock-up Agreement
Lead Underwriters
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel

Reported Broker Availability

No broker information available yet

Check back later for updates

Reported by users or publicly disclosed. Information is for reference only.

Important Links & Filings

SEC S-1 Filing →
Important: Information presented on this website is aggregated from publicly available sources and voluntary user submissions. It is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. IPO access and availability may vary by broker and is not guaranteed; always verify details directly with your broker before making any investment decisions. We are not affiliated with, endorsed by, or acting on behalf of any broker-dealers, underwriters, or issuing companies. Some links to broker platforms may be affiliate links, and we may earn a commission if you open an account through those links. See full disclaimer for additional information.